MIRNA BRAIN

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 拟议的研究将解决特定标志物的知识空白， 星形细胞瘤分类，可用作脑肿瘤侵袭性的预后和诊断标志物。拟议的合作项目将由基础科学和临床科学研究人员组成的跨学科小组进行。因此，该项目的目标是多方面的，涉及脑肿瘤的使用， 来自波多黎各个体的样本进行全基因组微RNA（miRNA）表达阵列。 为了响应波多黎各临床和转化研究联合会（PRCTRC）的主要任务之一，即解决少数民族人口之间的健康差距，该提案将改善少数民族机构研究人员对基础和转化癌症研究的参与。星形细胞瘤，星形胶质细胞的肿瘤，是最常见的中央型胶质瘤。 神经系统（CNS）肿瘤，占所有原发性脑肿瘤的60%以上。由于基于组织学的分类是高度主观的，因此需要更稳健的组织学独立的分子分类器。虽然不同的基因表达和全基因组阵列CGH表达谱已用于分类，但这些表达特征尚未转化为临床环境中的实用性，这表明这些研究需要进一步表征， 验证。微小RNA（miRNAs）是内源性的，短的（1924个核苷酸）的非蛋白质编码RNA，在转录后水平调节基因表达。在许多人类肿瘤中已经描述了许多miRNA的表达谱的改变。最近的证据表明，与组织学或基因表达分析相比，使用micromiRNA表达谱可以更好地分类星形细胞瘤的分级类型。此外，与大信使RNA（mRNA）转录物相比，短片段的miRNA更稳定，这便于它们的使用。 尽管不同的研究已经确定了不同脑肿瘤（包括恶性星形细胞瘤）中的miRNA表达模式，但尚未评估波多黎各肿瘤样本中星形细胞瘤根据其恶性潜力的miRNA表达特征。因此，本研究项目的目的是根据波多黎各脑肿瘤样本中星形细胞瘤的恶性潜能构建星形细胞瘤的micro-RNA（miRNA）表达谱。这项研究是相关的，因为这种miRNA谱可用于诊断，预测和/或预后因素，以及用于治疗目的。我们的总体假设是，根据波多黎各脑肿瘤样本中星形细胞瘤的恶性潜力（分级类型），在星形细胞瘤样本中观察到不同的miRNA表达特征。 为了验证这一假设，我们将进行以下研究： 具体目标1：根据波多黎各脑肿瘤标本中星形细胞瘤的恶性潜能，构建星形细胞瘤micro-RNA（miRNA）表达谱。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The proposed research will address a GAP IN KNOWLEDGE on specific markers for astrocytoma classification that can be used as prognostic and diagnostic markers of brain tumor aggressiveness. The proposed collaborative project will be carried out by an interdisciplinary team of researchers from basic and clinical sciences. Consequently, the objectives of the project, which centers on the broad topic of brain tumor research, are multi-pronged and involve the use of brain tumor samples from Puerto Rican individuals to perform genome-wide micro RNA (miRNA) expression arrays. In response to one of the main missions of the Puerto Rico Clinical and Translational Research Consortium (PRCTRC), which is to address health disparities among ethnic minority populations, this proposal will improve the participation of researchers of minority institutions in basic and translational cancer research. Astrocytoma, the tumor of astrocytic glial cells, is the most common type of central nervous system (CNS) neoplasms, accounting for more than 60% of all primary brain tumors. As histology-based classification is highly subjective, there is a need for more robust histologyindependent molecular classifiers. Although different gene expression and genome-wide array-CGH expression profiles have been use for classification, these expression signatures are yet to be translated to utility in clinical settings suggesting that these studies require further characterization and validation. Micro RNAs (miRNAs) are endogenous, short (1924 nucleotides) non-protein-coding RNAs that regulate gene expression at the post-transcriptional level. Alterations in the expression profiles of many miRNAs have been described in numerous human tumors. Recent evident indicate that the grade types of astrocytoma could be better classified by using a micro miRNA expression profiles compared with histological or gene expression analysis. In addition, short fragments of miRNAs are more stable compared with large messenger RNA (mRNAs) transcripts, which facilities their use. Although different studies have determined miRNA expression patters in different brain tumors, including malignant astrocytoma, miRNA expression signatures of astrocytoma according its malignant potential in Puerto Rican tumor samples have not been assessed. Thus, the OBJECTIVE of this research project is to construct a micro-RNA (miRNA) expression profile of astrocytoma according to its malignant potential in Puerto Rican brain tumor samples. This research is RELEVENT because this miRNA profile could be used for diagnostic, predictive and/or prognostic factor, as well as for therapeutic purposes. Our GENERAL HYPOTHESIS is that different miRNAs expression signatures are observed in astrocytoma samples according to its malignant potential (grade type) in Puerto Rican brain tumor samples. To test this hypothesis, we will pursue the following line of research: Specific Aim 1: To construct a micro-RNA (miRNA) expression profile of astrocytoma according to its malignant potential in Puerto Rican brain tumor samples.